Semaglutide, a GLP-1 receptor agonist, works by slowing stomach emptying, reducing appetite signals in your brain, and stimulating insulin release when blood sugar rises
Freshly Uncovered News and Studies In July 2023, a wave of stories emerged shedding light on the challenges faced by individuals using Ozempic and Wegovy who were later diagnosed with gastroparesis
Persistent fatigue or low energy related to excess weight
Adults taking Eli Lilly's Zepbound lost 47% more weight on average than those on Novo Nordisk's Wegovy, Lilly reported from the first head-to-head trial comparing the two blockbuster GLP-1 obesity drugs
Improved sleep quality: HRV can influence sleep quality, with higher HRV indicating more restful sleep
This is exactly what you would expect from a drug whose cardiac effects are driven by receptor activation, more drug means more receptor binding means more cAMP means faster heart rate